Meeting
2023 ASCO Annual Meeting
Novel genomic alterations and transcriptomic-based tumor microenvironment classification of sarcoma and their impact on treatment decision making.
Authors
Irina Zhuk
BostonGene, Corp., Waltham, MA
Irina Zhuk , Anna Novokreschchenova , Aida Aukhadieva , Sandrine Degryse , Aleksei Shevkoplias , Anna Belozerova , Krystle Nomie , Nikita Kotlov , Georgy Sagaradze , Lev Bedniagin , Linda Balabanian , Ekaterina Postovalova , Alexander Bagaev , Nathan Fowler , J Andrew Andrew Livingston , Vinod Ravi , Sant P. Chawla , Gregory Michael Cote
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Molecular Targets/Biomarkers/Tumor Biology
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11547)
DOI
10.1200/JCO.2023.41.16_suppl.11547
Abstract #
11547
Poster Bd #
481
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Next-generation sequencing (NGS) for identifying actionable molecular alterations in patients with newly diagnosed and recurrent IDHwt-glioblastoma (GBM): A large mono-institutional experience.
First Author: Marta Padovan
Poster
2019 ASCO Annual Meeting
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.
First Author: Erika Paige Hamilton
Poster
2014 ASCO Annual Meeting
Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in “pan-negative” lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history.
First Author: Alexander E. Drilon
Poster
2023 ASCO Annual Meeting
Exploratory novel biomarker and resistance mechanism of milademetan, an MDM2 inhibitor, in amplified MDM2 intimal sarcoma from an open-label phase 1b/2 trial (NCCH1806/MK004).
First Author: Takafumi Koyama